← Eichor
Study identifier: NCT07055152 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients

Condition: MINOCA · STEMI · Normal  ·  Sponsor: University of Pisa

PhaseN/A
Planned participants90
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersYes

About this study

The aim of this study is to evaluate microvascular dysfunction through OCTA in MINOCA patients. In order to better understand the condition, OCTA will also be performed in two matched patient groups: healthy controls and ACS patients. The study will compare the retinal microvascular parameters across these groups to determine differences in microvascular function in MINOCA patients. Additionally, in the MINOCA subgroup, the study will further evaluate the differences in microvascular dysfunction within specific subsets of patients (e.g., Takotsubo, vasospastic angina, microvascular angina, patients with evidence of plaque erosion) to understand the variability and potential mechanisms underlying each subgroup of MINOCA.

This description comes directly from the study's public registry record.

Talk to the study team

Mattia Alberti, Dr  ·  +393271946335  ·  mattia.alberti96@outlook.it

Always discuss trial participation with your own doctor first.

Locations (1)

University of Pisa, Cisanello HospitalPisa, Pisa, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07055152